Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective vigilantly but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the last several shares of mine. The 1st CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set out what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very promotional image in the Uptick Newswire employment interview which I came away with a bad opinion of the business.

Irony of irony, the poor impression of mine of the company has grown steadily, however, the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this know-how and linked intellectual property coming from Progenics to CytoDyn, and also roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 zillion) as well as the first new drug application endorsement ($5 million), as well as royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and many therapies, it’s this single therapies as well as a “broad pipeline of indications” as it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy in dozens of indications.

The opening banner of its on its website (below) shows an active organization with diverse interests albeit centered on leronlimab, several disease sorts, multiple publications in addition to multiple presentations.

Might it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself through the very beginning of my interest in this particular organization. Judging with the multiples of thousands of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this question.

CytoDyn is a traditional battleground, or maybe some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *